Novo Nordisk a S (NVO)
- Sector
- Pharmaceuticals
- Last price
- $38.12
- As of
Kresmion compiles this page from NVO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
NOVO NORDISK A S (NVO): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-13.
See the full NVO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NVO on one page. Preview it with sample data, then open it live with a free account.
Preview the NVO dossierActive signals for NVO
- highCONSENSUS_SELL
3 tracked funds reduced NVO this 2026Q2, institutional consensus
- highCONSENSUS_BUY
7 tracked funds increased NVO this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 91% of NVO (2026Q2)
- highCONSENSUS_BUY
4 tracked funds increased NVO this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +74% to NVO (2026Q2)
FREE, NO ACCOUNT
Every signal on NVO, as it fires
You are seeing 5 of 25 signals recorded on NVO since 2026-05-31.
The five above landed across 2 days. The other 20 were recorded on 3 other days. 19 of the 25 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NVO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 670100205 · 2026Q2 | $145.4M | 0.20% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 670100205 · 2026Q2 | $97.6M | 0.04% | , |
| CITADEL ADVISORS LLCCUSIP 670100205 · 2026Q2 | $65.5M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 670100205 · 2026Q2 | $33.4M | 0.02% | , |
| Point72 Asset Management, L.P.CUSIP 670100205 · 2026Q2 | $1.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 670100205 · 2026Q2 | $757K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NVO
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
NVO against its peers
NVO's operating margin of 41.3% ranks in the 97th percentile of 15 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-28 and 2025-12-31.
| Metric | NVO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 309B DKK | n/a | n/a | 0 |
| Revenue YoY | 6.4% | n/a | n/a | 3 |
| Gross margin | 81.0% | 67.9% | 85 | 9 |
| Operating margin | 41.3% | 8.5% | 97 | 15 |
| Net margin | 33.1% | 10.3% | 98 | 22 |
| Return on equity | 52.8% | 15.4% | 90 | 23 |
| P / E | n/a | 20.9x | n/a | 12 |
| 1 year | -31.6% | 31.0% | 6 | 24 |
Peers (25): PFE, BMY, AZN, NVS, GSK, MRK, TEVA, JNJ, ZTS, LLY, VTRS, JAZZ, CORT, AXSM, AMRX, OGN, AMLX, TARS, SUPN, LQDA, HRMY, BHC, XERS, TRVI, GPCR. Fiscal periods ending between 2025-12-28 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NVO: 20-F), reported in DKK. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow NVO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to NVO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.